Your browser doesn't support javascript.
loading
Developments in anti-complement therapy; from disease to clinical trial.
Harris, Claire L; Pouw, Richard B; Kavanagh, David; Sun, Ruyue; Ricklin, Daniel.
Afiliación
  • Harris CL; Complement Therapeutics Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK; National Renal Complement Therapeutics Centre, Building 26, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP,
  • Pouw RB; Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056, Basel, Switzerland.
  • Kavanagh D; Complement Therapeutics Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK; National Renal Complement Therapeutics Centre, Building 26, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP,
  • Sun R; Complement Therapeutics Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
  • Ricklin D; Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056, Basel, Switzerland. Electronic address: d.ricklin@unibas.ch.
Mol Immunol ; 102: 89-119, 2018 10.
Article en En | MEDLINE | ID: mdl-30121124
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas del Sistema Complemento / Proteínas Inactivadoras de Complemento / Desarrollo de Medicamentos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Immunol Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas del Sistema Complemento / Proteínas Inactivadoras de Complemento / Desarrollo de Medicamentos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Immunol Año: 2018 Tipo del documento: Article